<DOC>
	<DOCNO>NCT01000610</DOCNO>
	<brief_summary>In open-label single arm study safety efficacy Mabthera evaluate patient active rheumatoid arthritis inadequate response methotrexate . Patients receive MabThera ( 1000mg iv infusion ) day 1 15 , background methotrexate ( 10-25mg po sc weekly ) . After initial study period 24 week , eligible patient may receive 3 re-treatments MabThera . The anticipated time study treatment 1-2 year target sample size &lt; 50</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Patients With Rheumatoid Arthritis Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>adult patient &gt; /= 18 year age rheumatoid arthritis DAS28 &gt; /= 3.2 receive treatment outpatient basis experience inadequate response previous current treatment methotrexate rheumatic autoimmune disease RA , significant systemic involvement secondary RA history current inflammatory joint disease RA previous treatment celldepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>